Prostate cancer: A clinical and basic science review

Journal of Andrology

Volumn 18, Issue 1, 1997, Pages 15-20

  Long, Richard J ^a   Roberts, Kenneth P ^a   Wilson, Michael J ^a,b   Ercole, Cesar J ^a   Pryor, Jon L ^a,c  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b VA MEDICAL CENTER   (United States)

^c Department of Urologic Surgery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TRIFLURIDINE;

ANTIGEN DETECTION; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; ECHOGRAPHY; HUMAN; MALE; METASTASIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TRANSURETHRAL RESECTION;

HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0031042461     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Babaian RJ, Zagars GK, Ayala AG. Radiation therapy of stage C prostate cancer: significance of Gleason grade to survival. Sem Urol 1990; 8(4):225-231.
2. Benson MC, Whang IS, Pantuk A, Ring K, Kaplan SA, Olsson CA, Cooner WH. Prostate specific antigen density: a means of distinguishing between benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-816.
3. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB. Bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608.
4. Brawer MK, Aramburu EAG, Chen GL, Preston SD, Ellis WJ. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic adenocarcinoma. J Urol 1993a;150:369-373.
5. Brawer MK, Beatie J, Wener MH. PSA as the initial test in prostate screening: results of the third year. J Urol (Suppl) 1993b;149:299A.
6. Buttyan R, Sawckzuk IS, Benson MC, Siegal JD, Olsson CA. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 1987;11:327-337.
7. Cantrell BB, DeKlerk DP, Eggleston JC, Boitnott JK, Walsh PC. Pathological factors that influence prognosis in stage A prostate cancer: the influence of extent versus grade. J Urol 1981;125:516-520.
8. Carter HB, Hamper UM, Seth S, Sanders RC, Epstein JI, Walsh PS. Evaluation of transrectal ultrasound in the early detection of prostate cancer. J Urol 1989;142:1008-1010.
9. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters B, MacFarlane MT, Southwick PC. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-1290.
10. Chi S-G, deVere White RW, Meyer FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994;86:926-933.
11. Chodak GW, Keller P, Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal examination. J Urol 1989;141: 1136-1138.
12. Donohue RE, Fauver HE, Whitesel JA, Augsperger RR, Pfister RR. Influence of tumor grade on results of pelvic lymphadenectomy. Urology 1981;17(5):435-440.
13. Elder JS, Jewett HJ, Walsh PC. Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate. J Urol 1982;127:704-706.
14. Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol 1993;150:135-141.
15. Epstein JI, Paull G, Eggleston JC, Walsh PC. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. J Urol 1986;136:837-839.
16. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-1093.
17. Gilbertson VA. Cancer of the prostate gland. JAMA 1971;215(1):81-84.
18. Hanks GE, Asbell S, Krall JM, Perez CA, Doggett S, Rubin P, Sause W, Pilepich MV. Outcome for lymph node dissection negative T-1b, T-2 (A-2, B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int J Rad Onc Biol Phys 1991;21(4):1099-1103.
19. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991;256:271-282.
20. Huang HJ, Yee J-K, Shew J-Y, Chen P-L, Bookstein R, Freidmann T, Lee EY-H, Lee W-H. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 1988;242: 1563-1566.
21. Imai K, Zinbo S, Shimizu K, Yamanaka H, Kumasaka F, Sato Z. Clinical characteristics of prostate cancer detected by mass screening. Prostate 1988;12:199-207.
22. Isaacs WB, Bova GS, Morton RA, Bussemakers MJG, Brooks JD, Ewing GM. Molecular biology of prostate cancer. Semin Oncol 1994;21: 514-521.
23. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 allelles. Cancer Res 1991;51:4716-4720.
24. Israeli RS, Miller WH Jr, Su SL, Samadi DS, Powell CT, Heston WD, Wise GJ, Fair WR. Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate membrane-derived primers in the polymerase chain reaction. J Urol 1995;153:573-577.
25. Kabalin JN, Hodge KK, McNeal JE, Freiha FS, Stamey TA. Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 1989;142:326-331.
26. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pairente C, Goldwasser B, Karasik A. Serum insulin-like growth factor binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993;77:229-233.
27. Kim NW. Piatysze MA, Prowse KR, Harley CB, West MD, Ho PLC. Coviello GM, Wright WE. Weinrich SL. Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
28. Klocker H, Culig Z, Hobisch A, Cato ACB, Bartsch G. Androgen receptor alterations in prostatic carcinoma. Prostate 1994;25:266-273.
29. Komatsu K, Wehner N, Prestigiacomo AF, Chen Z, Stamey TA. Variation of serum prostate specific antigen in 814 men from a screening population: intra-individual assay variation is greater than the repeat assay variation. J Urol (Suppl) 1994;151:401A.
30. Kramolowsky EV. The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 1988;139:1242-1244.
31. Kyprianou N. Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J Urol 1994;12:299-303.
32. Larsen MP, Carter HB, Epstein JI. Can stage A1 tumor extent be predicted by transurethral resection tumor volume, percent or grade? A study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stages A2 and B disease. J Urol 1991;146:1059-1063.
33. Lee F, Littrup PJ, Torp-Pedersen ST, Mettlin C, McHugh TA, Gray JM, Kumasaka GH, McLeary RD. Prostate cancer: comparison of transrectal US and digital rectal examination for screening. Radiology 1988;168:389-394.
34. Leibel SA, Hanks, GE, Kramer S. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Int J Rad Onc Biol Phys 1984;10(3):401-409.
35. Lepor H, Kimball AW, Walsh PC. Cause-specific actuarial survival analysis: a useful method for reporting survival data in men with clinically localized carcinoma of the prostate. J Urol 1989;141:82-84.
36. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A, Badalament R, Babaian R. Cost effective prostate cancer detection. Cancer 1994; 74:3146-3158.
37. Mettlin C, Murphy GP, Ray P, Shanberg A, Toi A, Chesley A, Babaian R, Badalament R, Kane RA, Lee F. American Cancer Society - national prostate cancer detection project. Cancer 1993;71:891-898.
38. Middleton RG, Smith JA Jr, Melzer RB, Hamilton PE. Patient survival and local recurrence rate following radical prostatectomy for prostatic carcinoma. J Urol 1986;136:422-424.
39. Moul JW, Freidericks PA, Lance RS, Theune SM, Chang ES. Infrequent ras oncogene mutations in human prostate cancer. Prostate 1992;20: 327-338.
40. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-1669.
41. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men. JAMA 1993;270:860-864.
42. Pajough S, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT. Expression of metalloprotease genes in human prostate cancer. J Cancer Res Clin Oncol 1991;117:144-150.
43. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
44. Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT. Molecular and cellular changes associated with the acquisition of meta-static ability by prostatic cancer cells. Prostate 1994;25(5):249-265.
45. Sandberg AA. Chromosomal abnormalities and related events in prostate cancer. Hum Pathol 1992;23:368-382.
46. Scardino PT. Early detection of prostate cancer. Urol Clin N Am 1989; 16(4):635-655.
47. Scardino PT, Wheeler TM. Local control of prostate cancer with radio-therapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr 1988;7:95-103.
48. Schroeder FH, Belt E. Carcinoma of the prostate: a study of 213 patients with stage C tumors treated by total perineal prostatectomy. J Urol 1975;114:257-260.
49. Sikes RA, Chung LWK. Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene. Cancer Res 1991;52:3174-3181.
50. Sinha AA, Gleason DF, Staley NA, Wilson MJ, Sameni M, Sloane BF. Cathepsin B in angiogenesis of human prostate: an immunohisto-chemical and immunoelectron microscopic analysis. Anat Rec 1995; 241:353-362.
51. Steinberg GD, Epstein JI, Piantadosi S, Walsh PC. Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974-1987. J Urol 1990;144:1425-1432.
52. Thompson IM, Ernst JJ, Gangai MP, Spence CR. Adenocarcinoma of the prostate: results of routine urological screening. J Urol 1984;132:690-692.
53. Thompson IM, Rounder JB, Teague JL, Peek M, Spence CR. Impact of routine screening for adenocarcinoma of the prostate on stage distribution. J Urol 1987;137:424-426.
54. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res 1994;54:4096-4102.
55. Vieweg J, Boczkowski D, Roberson KM, Edwards DW, Philip M, Philip R, Rudoll T, Smith C, Robertson C, Gilboa E. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 1995; 55:2366-2372.
56. Walsh PC, Jewett HJ. Radical surgery for prostatic cancer. Cancer 1980; 45:1906-1911.
57. Wilson MJ, Proteases in prostate development, function, and pathology. Microsc Res Tech 1995;30:305-318.
58. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. Ca Cancer J Clin 1995;45:8-30.
59. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL. Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol 1992;6:2123-2128.
60. Zhau HE, Wan DS, Zhou J, Miller GJ, von Eschenbach AC. Expression of c-erbB-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinogen 1992;5:320-327.
61. Zincke H. Combined surgery and immediate adjuvant hormonal treatment for stage D1 adenocarcinoma of the prostate: Mayo Clinic experience. Sem Urol 1990;8(3):175-183.